GC Biopharma Signs Fabry Drug Licensing Deal With BioMarin
The licensing deal is worth up to USD 237.5 million.
Related stories
Warburg Pincus Announces Public Delisting Offer for PSI
Warburg Pincus announced a public acquisition offer for PSI on Oct. 20, 2026, in connection with a delisting.
M impact | MNA | Oct 30, 2026, 08:52 AM UTC
Evonik Rejects BASF Takeover Approach and Declines Negotiations
Evonik Industries said it will not enter takeover negotiations with BASF after reviewing a letter from the rival chemical company.
M impact | MNA | Oct 30, 2026, 08:38 AM UTC
Evonik Rejects Talks With BASF on Possible Takeover Offer
Evonik rejected negotiations with BASF regarding a possible takeover offer.
M impact | MNA | Oct 30, 2026, 08:17 AM UTC
Intesa Sanpaolo Makes €31 Billion Bid for MPS
The headline says the bid includes €800 million in cash and half of MPS branches going to Unipol.
M impact | MNA | Oct 30, 2026, 08:01 AM UTC
Air Liquide Cites More Than €4.1B in Investments and €2.85B DIG Airgas Deal
M impact | MNA | Oct 30, 2026, 08:01 AM UTC
Evonik to Let BASF Brief Board on Merger Rationale, Report Says
People close to Evonik say the company plans to let BASF explain the industrial logic of a merger to Evonik’s board.
M impact | MNA | Oct 30, 2026, 07:51 AM UTC